Results from one phase II study conducted in Spain showed that long-term Remune treatment was effective in delaying virologic failure during antiretroviral treatment interruption.
The second phase II study, conducted in Italy, demonstrated stabilization of CD4+ cell counts, as well as several positive trends in key markers believed to indicate immune responses against HIV disease in antiretroviral-naive patients treated with Remune.
“The positive virologic and immunologic trends, along with HIV-specific immune responses we are seeing in patients treated with Remune in both the Italian and Spanish studies are a powerful signal for us to continue the direction of our Remune clinical program,” said Dr John Bonfiglio, president and CEO of The Immune Response Corporation. “We look forward to sharing the detailed data with the scientific community at upcoming medical congresses.”